Gastric Cancer Medical Services in China

Gastric cancer, or adenocarcinoma of the stomach, is a malignant neoplasm arising from the gastric mucosa—most commonly in the distal antrum or cardia. Risk factors include chronic *Helicobacter pylori* infection, atrophic gastritis, intestinal metaplasia, dietary nitrosamines, smoking, and familial syndromes such as hereditary diffuse gastric cancer (CDH1 mutations). Early-stage disease is often asymptomatic; advanced presentations may include weight loss, hematemesis, melena, or abdominal pain. Diagnosis relies on upper gastrointestinal endoscopy with biopsy, staging via contrast-enhanced CT, EUS, and PET-CT where indicated. Treatment is multimodal: curative-intent surgery (D2 gastrectomy) remains cornerstone for resectable disease; perioperative chemotherapy (e.g., FLOT regimen) significantly improves survival. For unresectable or metastatic cases, targeted therapies (trastuzumab for HER2+, pembrolizumab for MSI-H/dMMR tumors) and immunotherapy are increasingly integrated into standard care.

China offers distinct advantages in gastric cancer management: its tertiary hospitals—especially those affiliated with Peking University Cancer Hospital, Fudan University Shanghai Cancer Center, and Sun Yat-sen University Cancer Center—rank among Asia’s top oncology institutions, with surgeons performing over 5,000 gastrectomies annually and publishing high-impact outcomes in *Annals of Oncology* and *JAMA Surgery*. Advanced technologies—including robotic-assisted laparoscopic gastrectomy, intraoperative fluorescence imaging, and next-generation sequencing–guided precision oncology—are widely deployed. Five-year overall survival for Stage II–III patients exceeds 60% in leading centers, comparable to U.S. and European benchmarks. Crucially, comprehensive treatment—including diagnostics, surgery, adjuvant therapy, and follow-up—costs 40–60% less than in the U.S., UK, or Singapore, without compromising clinical standards.

As a dedicated medical tourism agency, we facilitate seamless access to these resources for international patients: verifying hospital accreditation, coordinating multidisciplinary tumor board reviews, securing priority appointments, providing bilingual clinical liaisons, and delivering itemized, transparent pricing—covering all services from visa support to post-treatment rehabilitation. We ensure continuity of care, not just convenience.

Treatment Options & Itemized Cost Breakdown: Gastric Cancer (Oncology Department)

Non-Surgical / Medical Management

*Indicated for unresectable, metastatic, or medically inoperable cases; adjuvant/neoadjuvant settings.*

• •Chemotherapy (FOLFOX/XELOX):

- *Cost (per cycle)*: ¥8,500–¥12,000 → $1,180–$1,670 - *Includes*: Oxaliplatin (¥3,200), 5-FU/leucovorin or capecitabine (¥4,000–¥7,500), infusion nursing, IV access

• •Targeted Therapy (Trastuzumab for HER2+):

- *Cost (per 6 mg/kg dose)*: ¥14,200–¥16,800 → $1,970–$2,330

• •Immunotherapy (Sintilimab/Pembrolizumab):

- *Cost (per 200 mg dose)*: ¥7,800–¥9,500 → $1,080–$1,320

• •Supportive Lab/Exam Fees:

- Endoscopic biopsy + pathology (IHC/FISH): ¥1,800 → $250 - Blood counts, LFTs, renal panel (per cycle): ¥320 → $44

Surgical / Interventional Options

*Indicated for resectable localized or locally advanced disease (cT1b–cT4a, N0–N3, M0).*

• •Laparoscopic Gastrectomy (Distal/Subtotal):

- *Procedure cost*: ¥38,000–¥49,000 → $5,280–$6,810

• •Open Total Gastrectomy + D2 Lymphadenectomy:

- *Procedure cost*: ¥45,000–¥62,000 → $6,250–$8,610

• •Preoperative Workup (mandatory):

- PET-CT: ¥7,200 → $1,000 - Cardiopulmonary evaluation (echo + PFTs): ¥2,400 → $333 - Nutritional assessment + albumin prealbumin: ¥480 → $67

Special/Complex Condition Management

• •Palliative Stent Placement (for gastric outlet obstruction): ¥12,500–¥15,800 → $1,740–$2,200
• •HIPEC (Hyperthermic Intraperitoneal Chemotherapy) with cytoreduction: ¥85,000–¥112,000 → $11,800–$15,600 (requires peritoneal carcinomatosis, complete cytoreduction feasible)
• •Radiation Therapy (IMRT, 25 fractions): ¥28,000–¥36,000 → $3,900–$5,000 (used for positive margins or unresectable local disease)

Quick Selection Guide

• •<65 years, fit, localized tumor: Open total gastrectomy — optimal oncologic control; median cost $7,430.
• •65–75 years, mild COPD/diabetes: Laparoscopic distal gastrectomy — lower morbidity; median cost $6,045.
• •Metastatic, HER2+: Trastuzumab + chemo — first-line standard; monthly cost ~$3,300.
• •Budget-constrained (<$5,000 total): Palliative chemo (capecitabine monotherapy) — ¥4,200/cycle ($580); avoids surgery/intensive care.
• •Elderly (>80), frail, multiple comorbidities: Best supportive care + endoscopic stenting — avoids systemic toxicity; upfront cost $1,900.